Altimmune, Inc. (NASDAQ:ALT) Q4 2023 Results Conference Call March 27, 2024 8:30 AM ET Company Participants Scott Harris - CMO Vipin Garg - CEO Rich Eisenstadt - CFO Scot Roberts - CSO Conference Call Participants Corinne Jenkins - Goldman Sachs Jonathan Wolleben - JMP Liisa Bayko - Evercore Mayank Mamtani - B. Riley Patrick Trucchio - H.C. Wainwright Roger Song - Jefferies Seamus Fernandez - Guggenheim Yasmeen Rahimi - Piper Sandler Operator Good day, ladies and gentlemen, and welcome to the Altimmune Inc. ...

Exhibit 99.1 Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results Body composition study showed lean mass preservation, with only 25.5% of weight loss derived from lean mass Enrollment ongoing in IMPACT Phase 2b trial of pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH), with topline 24-week data expected Q1 2025 Preclinical study results showed a direct anti-fibrotic effect of pemvidutide in a non-steat ...

GAITHERSBURG, Md., March 20, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2023 financial results on Wednesday, March 27, 2024 and will provide a business update. Altimmune management will host a conference call at 8:30 am E.T. on March 27 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at http ...

GAITHERSBURG, Md., March 20, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2023 financial results on Wednesday, March 27, 2024 and will provide a business update. Altimmune management will host a conference call at 8:30 am E.T. on March 27 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at htt ...

Altimmune (NASDAQ: ALT) stock price continued its short squeeze this week, soaring to a high of $14.52, its highest point since February 6th last year. The company’s stock surged by more than 580% from its lowest level in 2023. This surge has brought its total market cap to over $608 million.Short squeeze continuesCopy link to sectionALT stock price has jumped sharply in the past few months in a high-volume environment. The most recent data shows that the three-month volume rose to $12.6 million. This week, ...

Altimmune (NASDAQ:ALT) stock is rising higher on Monday but it’s not actually due to any news from the clinical-stage biopharmaceutical company.Instead, a clinical trial update from rival Zealand Pharma is behind the increase in ALT stock today. That comes after the company provided results from a Phase 2 clinical trial of liver disease treatment and weight loss drug survodutide.The big news here is that the 6mg dose of the drug was found to be safe during the MASH liver disease clinical trial. That’s a hig ...

With new innovation, high demand for better treatment, pharmaceutical companies strengthening pipelines and a resurgence of mergers and acquisitions, biotech stocks could offer some of the most explosive opportunities of the year.“What’s more, big pharmaceutical companies with sizable piles of cash and the need to address patent expirations on some top-selling products later this decade will be hunting for companies with innovative drugs in development,” says Morningstar.com. In fact, some of the top acquis ...

Kerrisdale Capital is at it again, this time revealing a short position in struggling biotech firm Altimmune (NASDAQ:ALT). The acclaimed short seller has just released a damning short report on the company, saying that its only viable product, a weight-loss drug, has little chance of commercial success and will “bomb” in upcoming Phase 3 trials. As of this writing, ALT stock is down roughly 20%.Altimmune has been struggling for months, failing to demonstrate any real growth. Positive clinical trial results ...

Everyone knows that America has a major obesity problem. Because of this, new anti-obesity drugs are going to generate a great deal of revenue and profits their companies. What people don’t realize is that those weight-loss drugs come with high valuations and equities that reflect most of the profits they will generate. Consequently, investing in firms with lower valuations that are focused on improving or developing superior weight-loss treatments is a better way to go. Here are three weight-loss drug stoc ...

Key PointsViking Therapeutics has a dual GLP-1/GIP agonist in Phase 2 clinical trials for treating obesity and liver fat reduction for injectable and oral administration.Rhythm Pharmaceuticals has an FDA-approved treatment for the treatment of MC4R-pathway-related obesity disorders, including Bardet-Biedl Syndrome (BBS) and hyperphagia, an extreme, uncontrollable and compulsive compulsion to eat.Rhythm is a Phase 3 clinical trial for hypothalamic disorder (HO), a type of obesity caused by a damaged hypothal ...